Press Release

Research Article cites AlbuVoid™ in Targeted Proteomic Study of APOE in Alzheimer’s disease

MONMOUTH JUNCTION, NJ, November 20, 2025 — Biotech Support Group (BSG) reports on its NRicher™-derived product, AlbuVoid™, in a targeted proteomic analysis of astrocyte-specific APO E4 to E2 switching in a mouse model of Alzheimer’s disease.

Researchers from University of Kentucky, published an article entitled “Golden, Lesley R., et al. "APOE4 to APOE2 allelic switching in mice improves Alzheimer’s disease-related metabolic signatures, neuropathology and cognition." Nature Neuroscience (2025): 1-15.”, investigating a knock-in model that allows for an inducible ‘switch’ between risk and protective alleles (APOE4s2) related to Alzheimer’s disease.

Compared to individuals carrying two copies of the ε4 allele of apolipoprotein E (APOE), ε2 homozygotes have an approximate 99% reduction in late-onset Alzheimer’s disease (AD) risk. To investigate the in vivo effects of an APOE4 to APOE2 allelic switch, the study used APOE4s2loxP/loxP (APOE4s2) mice that express a floxed coding region (exon 4) of human APOE4 followed by exon 4 of human APOE2, and crossed to a tamoxifen (TAM)-activatable strain. Targeted LC-MS-based proteomic analysis was used to confirm the switch. 

The article states “Plasma ApoE was concentrated using the AlbuVoid Albumin Depletion Kit… Samples were eluted from the beads using a denaturing elution with elution buffer and 2× Laemmli loading buffer… Protein bands corresponding to ApoE (~36 kDa) were excised from the gel and subjected to a dithiothreitol reduction, iodoacetamide alkylation and in-gel trypsin digestion… subjected to LC–MS/MS analysis using the Q Exactive Orbitrap Mass Spectrometer. The overall ratio of E2 to E4 peptides detected in each sample was calculated as the total intensity for specific E4 or E2 peptides.”. This confirmed the E4 to E2 transition at the protein level, where 92–99% of the ApoE peptides detected in plasma from APOE4s2G mice were unique to E2.

The article concludes that astrocyte-specific E4 to E2 switching improves cognition, decreases amyloid pathology, lowers gliosis and reduces plaque-associated apolipoprotein E. Therefore, astrocyte-specific APOE replacement may be a viable strategy for future gene editing approaches to simultaneously reduce multiple AD-associated pathologies.

“Here is excellent example of how targeted protein enrichment can help determine closely related gene variants at the protein level. Our NRicher™ bead chemistry platform, of which AlbuVoid™ is one of many different chemistries, is perfectly suited to targeted plasma proteomics such as this, to distinguish closely related proteoforms using simple workflows.” stated Dr. Swapan Roy, President and Founder of Biotech Support Group.

For more information visit: AlbuVoid™ at
https://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm

And AlbuVoid™ LC-MS On-Bead For Serum/Plasma Proteomics, at

https://www.biotechsupportgroup.com/AlbuVoid-LC-MS-On-Bead-For-Serum-Proteomics-p/avb-ms.htm

For more information on our complete line of Albumin & IgG Removal, visit:

https://www.biotechsupportgroup.com/Albumin-Removal-s/307.htm

For more information on NRicher™ for family=specific and targeted proteomics, visit:

https://www.biotechsupportgroup.com/category-s/340.htm

About Biotech Support Group LLC
Biotech Support Group develops innovative sample preparation technologies that address the emerging needs of proteomics, biomarker discovery, and personalized medicine. Flagship products include Cleanascite™ for lipid removal, AlbuVoid™ and AlbuSorb™ PLUS for serum protein depletion, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance, family specific, and targeted proteome enrichment. These products support translational research by simplifying workflows and improving sample quality for downstream analysis.

For Business Development Inquiries:
Matthew Kuruc
Phone: 732-274-2866
Email: [email protected]

Keywords: AlbuVoid™, Albumin depletion, targeted LC-MS proteomics, ApoE variants, Alzheimer’s disease